Small study aims to pinpoint safer oxytocin dose for C-Section moms

NCT ID NCT05290129

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests different doses of oxytocin, a drug that helps the uterus contract after childbirth, to find the lowest effective dose for women having a C-section after labor. The goal is to prevent postpartum hemorrhage (heavy bleeding) while minimizing side effects. Forty women will be enrolled, and each woman's dose will be adjusted based on the previous participant's response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Oxytocin (Pitocin)
What this could lead to
If successful, this could identify a safer, lower dose of oxytocin to prevent dangerous bleeding after C-section, reducing side effects while still protecting mothers.
What could go wrong
This is a very small, early dose-finding study (40 participants) and may not apply to all women. The results are preliminary and need confirmation in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POSTPARTUM HEMORRHAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Postpartum Hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mount Sinai Hospital

    RECRUITING

    Toronto, Ontario, M5G1X5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.